Your browser is no longer supported. Please, upgrade your browser.
DVAX Dynavax Technologies Corporation daily Stock Chart
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-1.73 Insider Own0.50% Shs Outstand85.48M Perf Week5.54%
Market Cap844.28M Forward P/E- EPS next Y-0.53 Insider Trans194.70% Shs Float84.14M Perf Month26.38%
Income-128.80M PEG- EPS next Q-0.24 Inst Own65.20% Short Float14.95% Perf Quarter150.58%
Sales40.40M P/S20.90 EPS this Y15.10% Inst Trans-0.65% Short Ratio2.00 Perf Half Y58.50%
Book/sh0.14 P/B61.93 EPS next Y31.20% ROA-46.60% Target Price- Perf Year98.40%
Cash/sh1.33 P/C6.52 EPS next 5Y- ROE-737.40% 52W Range1.80 - 9.74 Perf YTD51.57%
Dividend- P/FCF- EPS past 5Y8.90% ROI-72.10% 52W High-10.99% Beta1.18
Dividend %- Quick Ratio5.00 Sales past 5Y26.10% Gross Margin50.50% 52W Low381.67% ATR0.87
Employees231 Current Ratio6.60 Sales Q/Q87.90% Oper. Margin- RSI (14)65.16 Volatility13.00% 10.25%
OptionableYes Debt/Eq15.22 EPS Q/Q76.30% Profit Margin- Rel Volume0.68 Prev Close8.31
ShortableNo LT Debt/Eq15.22 EarningsMay 07 AMC Payout- Avg Volume6.30M Price8.67
Recom1.70 SMA2026.08% SMA5054.11% SMA20073.65% Volume4,313,537 Change4.33%
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Jan-04-12Initiated MLV & Co Buy $8
Nov-09-10Reiterated Wedbush Outperform $6 → $8
Jul-05-20 09:16AM  
Jun-30-20 11:30AM  
Jun-22-20 11:28AM  
Jun-21-20 11:15PM  
Jun-19-20 07:41AM  
Jun-15-20 11:45AM  
Jun-10-20 09:30AM  
Jun-09-20 08:00AM  
Jun-04-20 06:37PM  
Jun-01-20 04:00PM  
May-30-20 05:12PM  
May-29-20 04:29PM  
May-28-20 04:05PM  
May-27-20 04:05PM  
May-22-20 10:19AM  
May-21-20 09:00PM  
May-20-20 01:18PM  
May-19-20 04:08PM  
May-14-20 09:24AM  
May-09-20 02:31PM  
May-07-20 04:10PM  
Apr-30-20 12:33PM  
Apr-28-20 04:10PM  
Apr-23-20 04:10PM  
Apr-20-20 08:15AM  
Apr-17-20 08:44AM  
Apr-16-20 07:30AM  
Apr-15-20 08:26AM  
Apr-13-20 06:12AM  
Apr-08-20 08:00AM  
Apr-02-20 04:30PM  
Apr-01-20 07:32AM  
Mar-26-20 11:56AM  
Mar-24-20 08:30AM  
Mar-13-20 07:38AM  
Mar-11-20 06:05PM  
Mar-04-20 12:30PM  
Mar-02-20 08:00AM  
Feb-28-20 07:55AM  
Feb-24-20 04:05PM  
Feb-18-20 04:05PM  
Feb-05-20 02:45PM  
Dec-17-19 07:56AM  
Dec-16-19 04:15PM  
Dec-13-19 12:00PM  
Dec-05-19 08:00AM  
Dec-03-19 08:30AM  
Nov-25-19 04:41AM  
Nov-21-19 11:32AM  
Nov-11-19 09:51AM  
Nov-07-19 04:05PM  
Nov-06-19 06:55PM  
Oct-30-19 10:34AM  
Oct-24-19 04:05PM  
Oct-15-19 07:01AM  
Oct-07-19 08:34AM  
Sep-30-19 04:05PM  
Aug-28-19 09:35PM  
Aug-27-19 02:39PM  
Aug-19-19 09:53AM  
Aug-12-19 04:05PM  
Aug-08-19 05:16PM  
Aug-07-19 06:45PM  
Jul-24-19 04:05PM  
Jul-23-19 11:00AM  
Jul-22-19 05:13PM  
Jul-19-19 09:56AM  
Jul-14-19 07:03PM  
Jul-11-19 11:55AM  
Jul-04-19 11:39AM  
Jun-27-19 11:19AM  
Jun-03-19 04:05PM  
Jun-01-19 02:15PM  
May-27-19 05:00AM  
May-26-19 05:03PM  
May-24-19 06:10PM  
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; and a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hack Andrew A. F.DirectorMay 27Buy5.001,000,0005,000,0008,525,000May 28 05:13 PM
Janssen RobertSenior Vice PresidentMay 19Sale6.3315,00094,950177,266May 19 07:05 PM
Janssen RobertSenior Vice PresidentMay 06Sale4.5228,000126,560192,266May 07 06:37 PM
Janssen RobertSenior Vice PresidentMay 05Sale4.439,00039,870220,266May 07 06:37 PM
Phillips Peggy VDirectorAug 12Buy3.0016,66649,99830,468Aug 12 07:27 PM
CANO FRANCISDirectorAug 12Buy3.0016,66750,00116,667Aug 12 07:24 PM
Novack David FCo-President and Senior VPAug 12Buy3.0016,66750,001118,484Aug 12 07:23 PM